Literature DB >> 21547024

Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?

Rachel Wuerstlein1, Ingo Bauerfeind.   

Abstract

SUMMARY: Metastatic breast cancer (MBC) is a chronic and incurable disease which can be kept steady for a long time with continuous oncologic therapy. There are various treatment options. Disease-free as well as overall survival were prolonged in many pharmaceutical studies. The therapist focuses on these oncologic parameters as well as the patient's quality of life. One central point of the communication between doctor and patient is the prediction by the medical team of how long to continue oncologic therapy and when to start palliative medicine in terms of best palliative care. Treatment options currently available for MBC as well as the importance of this difficult communication between the involved parties are pointed out. The end of tumor-specific oncologic therapy does not necessarily mean the end of therapeutic measures for the individual patient.

Entities:  

Year:  2011        PMID: 21547024      PMCID: PMC3083269          DOI: 10.1159/000324455

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN: 1661-3791            Impact factor:   2.860


  55 in total

1.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada.

Authors:  P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther
Journal:  J Natl Cancer Inst       Date:  2000-02-02       Impact factor: 13.506

Review 2.  Metastatic breast cancer: sequencing hormonal therapy and positioning of fulvestrant.

Authors:  I Vergote; F Amant; K Leunen; T Van Gorp; P Berteloot; P Neven
Journal:  Int J Gynecol Cancer       Date:  2006       Impact factor: 3.437

3.  Use of Palliative Performance Scale in end-of-life prognostication.

Authors:  Francis Lau; G Michael Downing; Mary Lesperance; Jack Shaw; Craig Kuziemsky
Journal:  J Palliat Med       Date:  2006-10       Impact factor: 2.947

4.  Communicating prognosis to patients with metastatic disease: what do they really want to know?

Authors:  P N Butow; S Dowsett; R Hagerty; M H N Tattersall
Journal:  Support Care Cancer       Date:  2001-09-07       Impact factor: 3.603

Review 5.  Pleurodesis for malignant pleural effusions.

Authors:  P Shaw; R Agarwal
Journal:  Cochrane Database Syst Rev       Date:  2004

6.  Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer.

Authors:  Ebru Sari; Gulnur Guler; Mutlu Hayran; Ibrahim Gullu; Kadri Altundag; Yavuz Ozisik
Journal:  Med Oncol       Date:  2010-01-23       Impact factor: 3.064

Review 7.  Patient centered decision making in palliative cancer treatment: a world of paradoxes.

Authors:  Hanneke de Haes; Nelleke Koedoot
Journal:  Patient Educ Couns       Date:  2003-05

Review 8.  Chemotherapy in metastatic breast cancer: A summary of all randomised trials reported 2000-2007.

Authors:  Nicholas Wilcken; Rachel Dear
Journal:  Eur J Cancer       Date:  2008-08-20       Impact factor: 9.162

Review 9.  The effects of surgery on tumor growth: a century of investigations.

Authors:  R Demicheli; M W Retsky; W J M Hrushesky; M Baum; I D Gukas
Journal:  Ann Oncol       Date:  2008-06-10       Impact factor: 32.976

10.  Recent advances in systemic therapy. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer.

Authors:  David W Miles
Journal:  Breast Cancer Res       Date:  2009-08-28       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.